{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:31:51Z","timestamp":1793460711318,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s11302-026-10188-w","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:40:32Z","timestamp":1790278832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ATP is not always pro-inflammatory: rethinking purinergic signalling in cancer and autoimmunity"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4454-6390","authenticated-orcid":false,"given":"Mohamed S.","family":"Nafie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7879-1357","authenticated-orcid":false,"given":"Mohamed K.","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"10188_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11302-023-09966-7","volume":"20","author":"SH Kiaie","year":"2024","unstructured":"Kiaie SH, Hatami Z, Nasr MS et al (2024) Pharmacological interaction and immune response of purinergic receptors in therapeutic modulation. Purinergic Signal 20:321\u2013343. https:\/\/doi.org\/10.1007\/s11302-023-09966-7","journal-title":"Purinergic Signal"},{"key":"10188_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051116","volume":"14","author":"JC Rotondo","year":"2022","unstructured":"Rotondo JC, Mazziotta C, Lanzillotti C et al (2022) The role of purinergic P2X7 receptor in inflammation and cancer: novel molecular insights and clinical applications. Cancers (Basel) 14:1116. https:\/\/doi.org\/10.3390\/cancers14051116","journal-title":"Cancers (Basel)"},{"key":"10188_CR3","doi-asserted-by":"publisher","first-page":"C832","DOI":"10.1152\/ajpcell.00053.2020","volume":"318","author":"F Di Virgilio","year":"2020","unstructured":"Di Virgilio F, Sarti AC, Coutinho-Silva R (2020) Purinergic signaling, DAMPs, and inflammation. Am J Physiol Cell Physiol 318:C832\u2013C835. https:\/\/doi.org\/10.1152\/ajpcell.00053.2020","journal-title":"Am J Physiol Cell Physiol"},{"key":"10188_CR4","doi-asserted-by":"crossref","unstructured":"Viero FT, Vilar Higa GS, Silva JB, et al (2026) Extracellular ATP and the central nervous system. In: ATP. Elsevier, pp 183\u2013204","DOI":"10.1016\/B978-0-443-30250-3.00038-2"},{"issue":"1","key":"10188_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41392-021-00553-z","volume":"6","author":"Z Huang","year":"2021","unstructured":"Huang Z, Xie N, Illes P et al (2021) From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther 6:162. https:\/\/doi.org\/10.1038\/s41392-021-00553-z","journal-title":"Signal Transduct Target Ther"},{"key":"10188_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11302-017-9593-0","volume":"14","author":"G Burnstock","year":"2018","unstructured":"Burnstock G, Knight GE (2018) The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signal 14:1\u201318. https:\/\/doi.org\/10.1007\/s11302-017-9593-0","journal-title":"Purinergic Signal"},{"key":"10188_CR7","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.2174\/0929867329666220322104552","volume":"30","author":"J Suwara","year":"2023","unstructured":"Suwara J, Radzikowska-Cieciura E, Chworos A, Pawlowska R (2023) The ATP-dependent pathways and human diseases. CMC 30:1232\u20131255. https:\/\/doi.org\/10.2174\/0929867329666220322104552","journal-title":"CMC"},{"key":"10188_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cells9071612","volume":"9","author":"ADR Campos-Contreras","year":"2020","unstructured":"Campos-Contreras ADR, D\u00edaz-Mu\u00f1oz M, V\u00e1zquez-Cuevas FG (2020) Purinergic signaling in the hallmarks of cancer. Cells 9:1612. https:\/\/doi.org\/10.3390\/cells9071612","journal-title":"Cells"},{"key":"10188_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-025-05465-5","volume":"63","author":"R Ebrahimi","year":"2026","unstructured":"Ebrahimi R, Hatami S, Hashempoor A et al (2026) Role of mitochondrial calcium dysregulation in Alzheimer\u2019s disease pathogenesis. Mol Neurobiol 63:214. https:\/\/doi.org\/10.1007\/s12035-025-05465-5","journal-title":"Mol Neurobiol"},{"key":"10188_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/JIR.S584582","volume":"19","author":"J Zhang","year":"2026","unstructured":"Zhang J, Li L, Guo Q et al (2026) ATP-P2X7R-NLRP3 axis as a unifying mechanism of ATP-induced cell death in degenerative bone and cardiovascular diseases. JIR 19:1\u201324. https:\/\/doi.org\/10.2147\/JIR.S584582","journal-title":"JIR"},{"key":"10188_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112496","volume":"9","author":"V Vultaggio-Poma","year":"2020","unstructured":"Vultaggio-Poma V, Sarti AC, Di Virgilio F (2020) Extracellular ATP: a feasible target for cancer therapy. Cells 9:2496. https:\/\/doi.org\/10.3390\/cells9112496","journal-title":"Cells"},{"key":"10188_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.694831","volume":"9","author":"F Grassi","year":"2021","unstructured":"Grassi F, De Ponte Conti B (2021) The P2X7 receptor in tumor immunity. Front Cell Dev Biol 9:694831. https:\/\/doi.org\/10.3389\/fcell.2021.694831","journal-title":"Front Cell Dev Biol"},{"key":"10188_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1058371","volume":"13","author":"J Kaur","year":"2023","unstructured":"Kaur J, Dora S (2023) Purinergic signaling: diverse effects and therapeutic potential in cancer. Front Oncol 13:1058371. https:\/\/doi.org\/10.3389\/fonc.2023.1058371","journal-title":"Front Oncol"},{"key":"10188_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814116","volume":"24","author":"F Grassi","year":"2023","unstructured":"Grassi F, Salina G (2023) The P2X7 receptor in autoimmunity. Int J Mol Sci 24:14116. https:\/\/doi.org\/10.3390\/ijms241814116","journal-title":"Int J Mol Sci"},{"key":"10188_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108700","volume":"262","author":"F Di Virgilio","year":"2024","unstructured":"Di Virgilio F, Vultaggio-Poma V, Tarantini M, Giuliani AL (2024) Overview of the role of purinergic signaling and insights into its role in cancer therapy. Pharmacol Ther 262:108700. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108700","journal-title":"Pharmacol Ther"},{"key":"10188_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane LM, Abdel-Hakeem MS, Wherry EJ (2019) CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol 37:457\u2013495. https:\/\/doi.org\/10.1146\/annurev-immunol-041015-055318","journal-title":"Annu Rev Immunol"},{"key":"10188_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.786595","volume":"12","author":"D Kobayashi","year":"2021","unstructured":"Kobayashi D, Sugiura Y, Umemoto E et al (2021) Extracellular ATP limits homeostatic T cell migration within lymph nodes. Front Immunol 12:786595. https:\/\/doi.org\/10.3389\/fimmu.2021.786595","journal-title":"Front Immunol"},{"key":"10188_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2023.101946","volume":"81","author":"A Mardomi","year":"2023","unstructured":"Mardomi A, KarajiBani M, Farnood F et al (2023) The frequency of peripheral PD-1+ TCD4+ cells is reversely associated with serum creatinine levels in recipients of kidney allografts. Transpl Immunol 81:101946. https:\/\/doi.org\/10.1016\/j.trim.2023.101946","journal-title":"Transpl Immunol"},{"key":"10188_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1743170","volume":"17","author":"M Charmoy","year":"2026","unstructured":"Charmoy M, Maier JM, Wyss T et al (2026) Memory-like CD8+ T cells lacking PD-1 adapt to persistent stimulation by reducing TCR signal transduction rather than increasing exhaustion. Front Immunol 17:1743170. https:\/\/doi.org\/10.3389\/fimmu.2026.1743170","journal-title":"Front Immunol"},{"key":"10188_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40364-025-00784-0","volume":"13","author":"Y Yang","year":"2025","unstructured":"Yang Y, Zhu L, Xu Y et al (2025) The progress and prospects of targeting the adenosine pathway in cancer immunotherapy. Biomark Res 13:75. https:\/\/doi.org\/10.1186\/s40364-025-00784-0","journal-title":"Biomark Res"},{"key":"10188_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/discim\/kyaf006","volume":"4","author":"C Williams","year":"2025","unstructured":"Williams C, Giovacchini D, Kennedy A et al (2025) CD28 and TCR differentially impact na\u00efve and memory T cell responses. Discovery Immunology 4:kyaf006. https:\/\/doi.org\/10.1093\/discim\/kyaf006","journal-title":"Discovery Immunology"},{"key":"10188_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.359","volume":"4","author":"Y Ai","year":"2023","unstructured":"Ai Y, Wang H, Liu L et al (2023) Purine and purinergic receptors in health and disease. MedComm 4:e359. https:\/\/doi.org\/10.1002\/mco2.359","journal-title":"MedComm"},{"key":"10188_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.654023","volume":"12","author":"M Lombardi","year":"2021","unstructured":"Lombardi M, Gabrielli M, Adinolfi E, Verderio C (2021) Role of ATP in extracellular vesicle biogenesis and dynamics. Front Pharmacol 12:654023. https:\/\/doi.org\/10.3389\/fphar.2021.654023","journal-title":"Front Pharmacol"},{"key":"10188_CR24","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1002\/eji.202249932","volume":"52","author":"R Winzer","year":"2022","unstructured":"Winzer R, Serracant-Prat A, Brock VJ et al (2022) P2X7 is expressed on human innate-like T lymphocytes and mediates susceptibility to ATP-induced cell death. Eur J Immunol 52:1805\u20131818. https:\/\/doi.org\/10.1002\/eji.202249932","journal-title":"Eur J Immunol"},{"key":"10188_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1646292","volume":"16","author":"X Li","year":"2025","unstructured":"Li X, Song S (2025) Dissecting the role of T cell exhaustion in cancer progression: a multifaceted approach. Front Immunol 16:1646292. https:\/\/doi.org\/10.3389\/fimmu.2025.1646292","journal-title":"Front Immunol"},{"key":"10188_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126673","volume":"25","author":"A Pegoraro","year":"2024","unstructured":"Pegoraro A, Grignolo M, Ruo L et al (2024) P2X7 variants in pathophysiology. Int J Mol Sci 25:6673. https:\/\/doi.org\/10.3390\/ijms25126673","journal-title":"Int J Mol Sci"},{"key":"10188_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252010874","volume":"25","author":"PT Santana","year":"2024","unstructured":"Santana PT, De Lima IS, Silva E Souza KCD et al (2024) Persistent activation of the P2X7 receptor underlies chronic inflammation and carcinogenic changes in the intestine. Int J Mol Sci 25:10874. https:\/\/doi.org\/10.3390\/ijms252010874","journal-title":"Int J Mol Sci"},{"key":"10188_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109333","volume":"224","author":"F Di Virgilio","year":"2023","unstructured":"Di Virgilio F, Vultaggio-Poma V, Falzoni S, Giuliani AL (2023) Extracellular ATP: a powerful inflammatory mediator in the central nervous system. Neuropharmacology 224:109333. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109333","journal-title":"Neuropharmacology"},{"key":"10188_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/02713683.2025.2553644","volume":"51","author":"Y Cao","year":"2026","unstructured":"Cao Y, Peng X, Luo S et al (2026) Reverse regulation of Th1 and Treg immune responses by P2X7 receptor: a possible cause of the progression of experimental autoimmune uveitis. Curr Eye Res 51:147\u2013156. https:\/\/doi.org\/10.1080\/02713683.2025.2553644","journal-title":"Curr Eye Res"},{"key":"10188_CR30","doi-asserted-by":"crossref","unstructured":"Sluyter R (2017) The P2X7 receptor. In: Atassi MZ (ed) Protein Reviews. Springer Singapore, Singapore, pp 17\u201353","DOI":"10.1007\/5584_2017_59"},{"key":"10188_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nri.2016.4","volume":"16","author":"C Cekic","year":"2016","unstructured":"Cekic C, Linden J (2016) Purinergic regulation of the immune system. Nat Rev Immunol 16:177\u2013192. https:\/\/doi.org\/10.1038\/nri.2016.4","journal-title":"Nat Rev Immunol"},{"key":"10188_CR32","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2174\/187152712803581137","volume":"11","author":"C Volonte","year":"2012","unstructured":"Volonte C, Apolloni S, D. Skaper S, Burnstock G (2012) P2X7 receptors: channels, pores and more. CNSNDDT 11:705\u2013721. https:\/\/doi.org\/10.2174\/187152712803581137","journal-title":"CNSNDDT"},{"key":"10188_CR33","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.tcb.2018.01.005","volume":"28","author":"F Di Virgilio","year":"2018","unstructured":"Di Virgilio F, Schmalzing G, Markwardt F (2018) The elusive P2X7 macropore. Trends Cell Biol 28:392\u2013404. https:\/\/doi.org\/10.1016\/j.tcb.2018.01.005","journal-title":"Trends Cell Biol"},{"key":"10188_CR34","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.4049\/jimmunol.179.3.1913","volume":"179","author":"Y Qu","year":"2007","unstructured":"Qu Y, Franchi L, Nunez G, Dubyak GR (2007) Nonclassical IL-1\u03b2 secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J Immunol 179:1913\u20131925. https:\/\/doi.org\/10.4049\/jimmunol.179.3.1913","journal-title":"J Immunol"},{"key":"10188_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cyto.2019.03.019","volume":"119","author":"Y Yu","year":"2019","unstructured":"Yu Y, Feng S, Wei S et al (2019) Extracellular ATP activates P2X7R-NF-\u03baB (p65) pathway to promote the maturation of bone marrow-derived dendritic cells of mice. Cytokine 119:175\u2013181. https:\/\/doi.org\/10.1016\/j.cyto.2019.03.019","journal-title":"Cytokine"},{"key":"10188_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21144937","volume":"21","author":"E Rivas-Y\u00e1\u00f1ez","year":"2020","unstructured":"Rivas-Y\u00e1\u00f1ez E, Barrera-Avalos C, Parra-Tello B et al (2020) P2X7 receptor at the crossroads of T cell fate. Int J Mol Sci 21:4937. https:\/\/doi.org\/10.3390\/ijms21144937","journal-title":"Int J Mol Sci"},{"key":"10188_CR37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/bph.15951","volume":"180","author":"A Baroja-Mazo","year":"2023","unstructured":"Baroja-Mazo A, Pe\u00f1\u00edn-Franch A, Lucas-Ruiz F et al (2023) P2X7 receptor activation impairs antitumour activity of natural killer cells. British J Pharmacology 180:111\u2013128. https:\/\/doi.org\/10.1111\/bph.15951","journal-title":"British J Pharmacology"},{"key":"10188_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0545-9","volume":"7","author":"AS Kashyap","year":"2019","unstructured":"Kashyap AS, Thelemann T, Klar R et al (2019) Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity. J Immunother Cancer 7:67. https:\/\/doi.org\/10.1186\/s40425-019-0545-9","journal-title":"J Immunother Cancer"},{"key":"10188_CR39","doi-asserted-by":"publisher","first-page":"366","DOI":"10.4049\/immunohorizons.2200089","volume":"7","author":"MC Warren","year":"2023","unstructured":"Warren MC, Matissek S, Rausch M et al (2023) SRF617 is a potent inhibitor of CD39 with immunomodulatory and antitumor properties. ImmunoHorizons 7:366\u2013379. https:\/\/doi.org\/10.4049\/immunohorizons.2200089","journal-title":"ImmunoHorizons"},{"key":"10188_CR40","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1838036","volume":"12","author":"BN Spatola","year":"2020","unstructured":"Spatola BN, Lerner AG, Wong C et al (2020) Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism. MAbs 12:1838036. https:\/\/doi.org\/10.1080\/19420862.2020.1838036","journal-title":"MAbs"},{"key":"10188_CR41","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s11302-025-10102-w","volume":"21","author":"J Guo","year":"2025","unstructured":"Guo J, Tang Y, Illes P (2025) The enzymatic degradation of ATP to adenosine by microglial CD39 regulates neurovascular coupling and metabolic supply to the brain. Purinergic Signal 21:979\u2013981. https:\/\/doi.org\/10.1007\/s11302-025-10102-w","journal-title":"Purinergic Signal"},{"key":"10188_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ph13090260","volume":"13","author":"G Magni","year":"2020","unstructured":"Magni G, Ceruti S (2020) Adenosine signaling in autoimmune disorders. Pharmaceuticals (Basel) 13:260. https:\/\/doi.org\/10.3390\/ph13090260","journal-title":"Pharmaceuticals (Basel)"},{"key":"10188_CR43","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3389\/fphar.2020.00793","volume":"11","author":"R Lara","year":"2020","unstructured":"Lara R, Adinolfi E, Harwood CA et al (2020) P2X7 in cancer: from molecular mechanisms to therapeutics. Front Pharmacol 11:793. https:\/\/doi.org\/10.3389\/fphar.2020.00793","journal-title":"Front Pharmacol"},{"key":"10188_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/biom12070983","volume":"12","author":"V Vultaggio-Poma","year":"2022","unstructured":"Vultaggio-Poma V, Di Virgilio F (2022) P2 receptors: novel disease markers and metabolic checkpoints in immune cells. Biomolecules 12:983. https:\/\/doi.org\/10.3390\/biom12070983","journal-title":"Biomolecules"},{"key":"10188_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01733-x","volume":"22","author":"C Xia","year":"2023","unstructured":"Xia C, Yin S, To KKW, Fu L (2023) CD39\/CD73\/A2AR pathway and cancer immunotherapy. Mol Cancer 22:44. https:\/\/doi.org\/10.1186\/s12943-023-01733-x","journal-title":"Mol Cancer"},{"key":"10188_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-026-03031-z","author":"M Molenda","year":"2026","unstructured":"Molenda M, Jarczak J, Kieszek P et al (2026) Single-cell architecture of purinergic signaling in human cord blood hematopoietic stem and progenitor cells. Leukemia. https:\/\/doi.org\/10.1038\/s41375-026-03031-z","journal-title":"Leukemia"},{"key":"10188_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1297775","volume":"13","author":"G Zhang","year":"2024","unstructured":"Zhang G, Liao J, Liu Y et al (2024) Ion channel P2X7 receptor in the progression of cancer. Front Oncol 13:1297775. https:\/\/doi.org\/10.3389\/fonc.2023.1297775","journal-title":"Front Oncol"},{"key":"10188_CR48","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41568-018-0037-0","volume":"18","author":"F Di Virgilio","year":"2018","unstructured":"Di Virgilio F, Sarti AC, Falzoni S et al (2018) Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer 18:601\u2013618. https:\/\/doi.org\/10.1038\/s41568-018-0037-0","journal-title":"Nat Rev Cancer"},{"key":"10188_CR49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/onc.2016.206","volume":"36","author":"F Di Virgilio","year":"2017","unstructured":"Di Virgilio F, Adinolfi E (2017) Extracellular purines, purinergic receptors and tumor growth. Oncogene 36:293\u2013303. https:\/\/doi.org\/10.1038\/onc.2016.206","journal-title":"Oncogene"},{"key":"10188_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241813906","volume":"24","author":"E Adinolfi","year":"2023","unstructured":"Adinolfi E, De Marchi E, Grignolo M et al (2023) The P2X7 receptor in oncogenesis and metastatic dissemination: new insights on vesicular release and adenosinergic crosstalk. Int J Mol Sci 24:13906. https:\/\/doi.org\/10.3390\/ijms241813906","journal-title":"Int J Mol Sci"},{"key":"10188_CR51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11302-015-9493-0","volume":"12","author":"G Burnstock","year":"2016","unstructured":"Burnstock G (2016) P2X ion channel receptors and inflammation. Purinergic Signal 12:59\u201367. https:\/\/doi.org\/10.1007\/s11302-015-9493-0","journal-title":"Purinergic Signal"},{"key":"10188_CR52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11302-026-10140-y","volume":"22","author":"H \u00dcst\u00fcnda\u011f","year":"2026","unstructured":"\u00dcst\u00fcnda\u011f H (2026) The P2X7 receptor\/NLRP3 inflammasome signaling axis in sepsis: molecular mechanisms, organ-specific pathophysiology, and emerging therapeutic strategies. Purinergic Signal 22:26. https:\/\/doi.org\/10.1007\/s11302-026-10140-y","journal-title":"Purinergic Signal"},{"key":"10188_CR53","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41423-019-0201-9","volume":"17","author":"X Dong","year":"2020","unstructured":"Dong X, Zheng Z, Lin P et al (2020) ACPAs promote IL-1\u03b2 production in rheumatoid arthritis by activating the NLRP3 inflammasome. Cell Mol Immunol 17:261\u2013271. https:\/\/doi.org\/10.1038\/s41423-019-0201-9","journal-title":"Cell Mol Immunol"},{"key":"10188_CR54","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.4049\/jimmunol.2000222","volume":"205","author":"M Li","year":"2020","unstructured":"Li M, Yang C, Wang Y et al (2020) The expression of P2X7 receptor on Th1, Th17, and regulatory T cells in patients with systemic lupus erythematosus or rheumatoid arthritis and its correlations with active disease. J Immunol 205:1752\u20131762. https:\/\/doi.org\/10.4049\/jimmunol.2000222","journal-title":"J Immunol"},{"key":"10188_CR55","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.neuint.2010.08.021","volume":"57","author":"T Grygorowicz","year":"2010","unstructured":"Grygorowicz T, Stru\u017cy\u0144ska L, Sulkowski G et al (2010) Temporal expression of P2X7 purinergic receptor during the course of experimental autoimmune encephalomyelitis. Neurochem Int 57:823\u2013829. https:\/\/doi.org\/10.1016\/j.neuint.2010.08.021","journal-title":"Neurochem Int"},{"key":"10188_CR56","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10787-018-0528-3","volume":"27","author":"T Grygorowicz","year":"2019","unstructured":"Grygorowicz T, Stru\u017cy\u0144ska L (2019) Early P2X7R-dependent activation of microglia during the asymptomatic phase of autoimmune encephalomyelitis. Inflammopharmacology 27:129\u2013137. https:\/\/doi.org\/10.1007\/s10787-018-0528-3","journal-title":"Inflammopharmacology"},{"key":"10188_CR57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1742-2094-5-33","volume":"5","author":"AJ Sharp","year":"2008","unstructured":"Sharp AJ, Polak PE, Simonini V et al (2008) P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis. J Neuroinflammation 5:33. https:\/\/doi.org\/10.1186\/1742-2094-5-33","journal-title":"J Neuroinflammation"},{"key":"10188_CR58","doi-asserted-by":"publisher","first-page":"9525","DOI":"10.1523\/JNEUROSCI.0579-07.2007","volume":"27","author":"C Matute","year":"2007","unstructured":"Matute C, Torre I, P\u00e9rez-Cerd\u00e1 F et al (2007) P2X7 receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci 27:9525\u20139533. https:\/\/doi.org\/10.1523\/JNEUROSCI.0579-07.2007","journal-title":"J Neurosci"},{"key":"10188_CR59","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1002\/art.38174","volume":"65","author":"J Zhao","year":"2013","unstructured":"Zhao J, Wang H, Dai C et al (2013) P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3\/ASC\/Caspase 1 pathway. Arthritis Rheum 65:3176\u20133185. https:\/\/doi.org\/10.1002\/art.38174","journal-title":"Arthritis Rheum"},{"key":"10188_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00435","volume":"10","author":"F Furini","year":"2019","unstructured":"Furini F, Giuliani AL, Parlati ME et al (2019) P2X7 receptor expression in patients with serositis related to systemic lupus erythematosus. Front Pharmacol 10:435. https:\/\/doi.org\/10.3389\/fphar.2019.00435","journal-title":"Front Pharmacol"},{"key":"10188_CR61","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1084\/jem.20171976","volume":"216","author":"CE Faliti","year":"2019","unstructured":"Faliti CE, Gualtierotti R, Rottoli E et al (2019) P2X7 receptor restrains pathogenic Tfh cell generation in systemic lupus erythematosus. J Exp Med 216:317\u2013336. https:\/\/doi.org\/10.1084\/jem.20171976","journal-title":"J Exp Med"},{"key":"10188_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.617211","volume":"11","author":"S Sharma","year":"2021","unstructured":"Sharma S, Kalra H, Akundi RS (2021) Extracellular ATP mediates cancer cell migration and invasion through increased expression of cyclooxygenase 2. Front Pharmacol 11:617211. https:\/\/doi.org\/10.3389\/fphar.2020.617211","journal-title":"Front Pharmacol"},{"key":"10188_CR63","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41419-026-08730-0","volume":"17","author":"DC Gorecki","year":"2026","unstructured":"Gorecki DC, Adinolfi E, Adriouch S et al (2026) Methodological guidelines for P2X receptor assays and data interpretation. Cell Death Dis 17:521. https:\/\/doi.org\/10.1038\/s41419-026-08730-0","journal-title":"Cell Death Dis"},{"key":"10188_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262110265","volume":"26","author":"JSY Cheah","year":"2025","unstructured":"Cheah JSY, Skarratt KK, Fuller SJ, Balle T (2025) Genetic variations in the P2X7 receptor: opportunities and challenges for drug development. Int J Mol Sci 26:10265. https:\/\/doi.org\/10.3390\/ijms262110265","journal-title":"Int J Mol Sci"},{"key":"10188_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/cells13020161","volume":"13","author":"M Tewari","year":"2024","unstructured":"Tewari M, Michalski S, Egan TM (2024) Modulation of microglial function by ATP-gated P2X7 receptors: studies in rat, mice and human. Cells 13:161. https:\/\/doi.org\/10.3390\/cells13020161","journal-title":"Cells"},{"key":"10188_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1287310","volume":"14","author":"RM Sainz","year":"2023","unstructured":"Sainz RM, Rodriguez-Quintero JH, Maldifassi MC et al (2023) Tumour immune escape via P2X7 receptor signalling. Front Immunol 14:1287310. https:\/\/doi.org\/10.3389\/fimmu.2023.1287310","journal-title":"Front Immunol"},{"key":"10188_CR67","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1158\/0008-5472.CAN-24-4624","volume":"85","author":"X Wang","year":"2025","unstructured":"Wang X, Jiang S-H, Ma M et al (2025) P2 purinergic receptors in tumor immunity. Cancer Res 85:3826\u20133841. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-4624","journal-title":"Cancer Res"},{"key":"10188_CR68","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s43556-025-00345-9","volume":"6","author":"J Shen","year":"2025","unstructured":"Shen J, Liao B, Gong L et al (2025) CD39 and CD73: biological functions, diseases and therapy. Mol Biomed 6:97. https:\/\/doi.org\/10.1186\/s43556-025-00345-9","journal-title":"Mol Biomed"},{"key":"10188_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.149513","volume":"707","author":"Y Zou","year":"2024","unstructured":"Zou Y, Li J, Chai J et al (2024) The impact of the P2X7 receptor on the tumor immune microenvironment and its effects on tumor progression. Biochem Biophys Res Commun 707:149513. https:\/\/doi.org\/10.1016\/j.bbrc.2024.149513","journal-title":"Biochem Biophys Res Commun"},{"key":"10188_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27073169","volume":"27","author":"J Ren","year":"2026","unstructured":"Ren J, Gong Z, Zhong Y et al (2026) Extracellular ATP functions as a metabolic lineage selection signal that stabilizes Tc9 cells during adoptive T cell therapy. IJMS 27:3169. https:\/\/doi.org\/10.3390\/ijms27073169","journal-title":"IJMS"},{"key":"10188_CR71","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2217\/fon-2023-0871","volume":"20","author":"N Kaplinsky","year":"2024","unstructured":"Kaplinsky N, Williams K, Watkins D et al (2024) Regulatory role of CD39 and CD73 in tumor immunity. Future Oncol 20:1367\u20131380. https:\/\/doi.org\/10.2217\/fon-2023-0871","journal-title":"Future Oncol"},{"key":"10188_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.947885","volume":"13","author":"H Aria","year":"2022","unstructured":"Aria H, Rezaei M, Nazem S et al (2022) Purinergic receptors are a key bottleneck in tumor metabolic reprogramming: the prime suspect in cancer therapeutic resistance. Front Immunol 13:947885. https:\/\/doi.org\/10.3389\/fimmu.2022.947885","journal-title":"Front Immunol"},{"key":"10188_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119434","volume":"24","author":"K Zab\u0142ocki","year":"2023","unstructured":"Zab\u0142ocki K, G\u00f3recki DC (2023) The role of P2X7 purinoceptors in the pathogenesis and treatment of muscular dystrophies. Int J Mol Sci 24:9434. https:\/\/doi.org\/10.3390\/ijms24119434","journal-title":"Int J Mol Sci"},{"key":"10188_CR74","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1021\/acsptsci.5c00446","volume":"8","author":"R Winzer","year":"2025","unstructured":"Winzer R, Hiefner J, Hackbusch R et al (2025) Reliable determination of ATP and its metabolites by LC-MS using blood collection tubes with and without ectonucleotidase inhibitors. ACS Pharmacol Transl Sci 8:4326\u20134334. https:\/\/doi.org\/10.1021\/acsptsci.5c00446","journal-title":"ACS Pharmacol Transl Sci"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10188-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-026-10188-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10188-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:06:19Z","timestamp":1793459179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-026-10188-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10188"],"URL":"https:\/\/doi.org\/10.1007\/s11302-026-10188-w","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"5 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}],"article-number":"76"}}